Information  X 
Enter a valid email address

Proteome Sciences (PRM)

  Print   

Friday 26 June, 2020

Proteome Sciences

AGM Statement

RNS Number : 2148R
Proteome Sciences PLC
26 June 2020
 

26 June 2020

 

 

 

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Annual General Meeting (AGM) Statement

 

At the Company's AGM being held today at 11.00 am, the Chairman, Christopher Pearce, will make the following statement:

 

"Following the delivery of a profit after tax in 2019, we are pleased to report continued progress throughout the business. We have experienced good growth in services revenues and sales of both TMT® and TMTpro™ have remained stable over the first 5 months of the year. Despite the challenges of the COVID-19 pandemic, our dedicated staff have ensured we remained fully operational and have delivered 11 projects carried over from 2019 for which we already had samples. A further 10 projects are ongoing and new orders are also being generated. We expect these positive trends to continue through the rest of the year".   

 

 

For further information:

 

Proteome Sciences plc

Dr Ian Pike, Interim Chief Executive Officer & Chief Scientific Officer

 

Richard Dennis, Chief Commercial Officer

Tel: +44 (0)20 7043 2116

 

Allenby Capital Limited (AIM Nominated Adviser & Broker) 

John Depasquale / Jeremy Porter

Tel: +44 (0) 20 3328 5656

 

About Proteome Sciences plc. ( www.proteomics.com )

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
AGMFFMPTMTJTMJM

a d v e r t i s e m e n t